【摘要】 肿瘤的分子靶向治疗逐渐成为肿瘤治疗的关注焦点,分子靶向药物的出现为肿瘤的治疗带来了新的方向。伊马替尼的应用极大地提高了胃肠道间质瘤的生存率,然而其疗效评价的方法、服药的时间、是否可以中断治疗、耐药后的治疗及靶向治疗与外科治疗的结合仍是目前研究的热点。更多还原

【Abstract】 Targeted therapy has gradually become the focus in the treatment of tumor,with the emerge of more and more targeted drugs which has brought the treatment of tumor into a new era.Imatinib,the tyrosine kinase inhibitor,is one of the important types of targeted therapy,has become the standard of care in adjuvant therapy of gastrointestinal stromal tumor(GIST) with extraordinary effects.However,the questions are still on debate incluing the optimal way to evaluate treatment results,the treatment duration,whether it can be intermitted or not,second line therapy for imatinibintolerance or-resistance and the combination with surgery.更多还原